Insider Buying: Diaceutics PLC (LON:DXRX) Insider Purchases 39,934 Shares of Stock

Diaceutics PLC (LON:DXRX) insider Graham Paterson purchased 39,934 shares of the company’s stock in a transaction that occurred on Wednesday, May 22nd. The shares were purchased at an average cost of GBX 129 ($1.64) per share, for a total transaction of £51,514.86 ($65,473.89).

Graham Paterson also recently made the following trade(s):

• On Wednesday, March 6th, Graham Paterson purchased 33,564 shares of Diaceutics stock. The shares were purchased at an average cost of GBX 99 ($1.26) per share, for a total transaction of £33,228.36 ($42,232.28).

Diaceutics Price Performance

DXRX opened at GBX 127.50 ($1.62) on Friday. The company has a debt-to-equity ratio of 3.07, a current ratio of 7.99 and a quick ratio of 9.92. The company’s 50-day moving average is GBX 105.23 and its 200 day moving average is GBX 97.26. Diaceutics PLC has a fifty-two week low of GBX 79 ($1.00) and a fifty-two week high of GBX 129.53 ($1.65). The firm has a market capitalization of £107.65 million, a P/E ratio of 10,500.00 and a beta of 0.47.

Analysts Set New Price Targets

Separately, Canaccord Genuity Group reissued a “buy” rating and set a GBX 150 ($1.91) price target on shares of Diaceutics in a research report on Tuesday, May 21st.

About Diaceutics

Diaceutics PLC, a diagnostic commercialisation company, provides data, data analytics, and implementation services for pharmaceutical companies worldwide. It operates DXRX platform, which offers DXRX data solutions, including access to various pipelines of diagnostic testing data from a network of laboratories that provides DXRX signal, lab mapping, testing dashboard, and physician mapping services; DXRX marketplace solutions, which enables a marketplace, where labs, pharma, and diagnostic companies come to find partners for collaborations on precision medicine diagnostics.